BRIEF-Apogee Therapeutics Announces Positive Interim Phase 1 Results From The APG990 Healthy Volunteer Trial

Reuters

03 Mar

BRIEF-<a href="https://laohu8.com/S/APGE">Apogee Therapeutics</a> Announces Positive Interim Phase 1 Results From The APG990 Healthy Volunteer Trial

March 3 (Reuters) - Apogee Therapeutics APGE.O:

APOGEE THERAPEUTICS ANNOUNCES POSITIVE INTERIM PHASE 1 RESULTS FROM THE APG990 HEALTHY VOLUNTEER TRIAL, UNLOCKING POTENTIAL MAINTENANCE DOSING EVERY THREE AND SIX MONTHS FOR APG279 (APG777 + APG990)
APOGEE THERAPEUTICS INC - APG990 WELL TOLERATED UP TO 1,200MG DOSES
APOGEE THERAPEUTICS INC - MOST COMMON ADVERSE EVENT FOR APG990 WAS HEADACHE
APOGEE THERAPEUTICS INC - NO SEVERE ADVERSE EVENTS OR STUDY DISCONTINUATIONS FOR APG990
APOGEE THERAPEUTICS INC - TO INITIATE PHASE 1B TRIAL OF APG279 AGAINST DUPIXENT IN 2025

Source text: ID:nGNX4V8GW9

Further company coverage: APGE.O

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2516001681"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2516001681\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2516001681?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-03-03 19:10","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2516001681","market":"nz","top_or_hot":-1,"title":"BRIEF-Apogee Therapeutics Announces Positive Interim Phase 1 Results From The APG990 Healthy Volunteer Trial","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-<a href=\"https://laohu8.com/S/APGE\">Apogee Therapeutics</a> Announces Positive Interim Phase 1 Results From The APG990 Healthy Volunteer Trial</title></head><body><p><span>March 3 (Reuters)</span><span> - </span>Apogee <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> <span>APGE.O</span>:</p><ul><li><p>APOGEE THERAPEUTICS ANNOUNCES POSITIVE INTERIM PHASE 1 RESULTS FROM THE APG990 HEALTHY VOLUNTEER TRIAL, UNLOCKING POTENTIAL MAINTENANCE DOSING EVERY THREE AND SIX MONTHS FOR APG279 (APG777 + APG990)</p></li><li><p>APOGEE THERAPEUTICS INC - APG990 WELL TOLERATED UP TO 1,200MG DOSES</p></li><li><p>APOGEE THERAPEUTICS INC - MOST COMMON ADVERSE EVENT FOR APG990 WAS HEADACHE</p></li><li><p>APOGEE THERAPEUTICS INC - NO SEVERE ADVERSE EVENTS OR STUDY DISCONTINUATIONS FOR APG990</p></li><li><p>APOGEE THERAPEUTICS INC - TO INITIATE PHASE 1B TRIAL OF APG279 AGAINST DUPIXENT IN 2025</p></li></ul><p>Source text: <span>ID:nGNX4V8GW9</span></p><p>Further company coverage: <span>APGE.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Apogee Therapeutics Announces Positive Interim Phase 1 Results From The APG990 Healthy Volunteer Trial</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Apogee Therapeutics Announces Positive Interim Phase 1 Results From The APG990 Healthy Volunteer Trial\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-03-03 19:10</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-<a href=\"https://laohu8.com/S/APGE\">Apogee Therapeutics</a> Announces Positive Interim Phase 1 Results From The APG990 Healthy Volunteer Trial</title></head><body><p><span>March 3 (Reuters)</span><span> - </span>Apogee <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> <span>APGE.O</span>:</p><ul><li><p>APOGEE THERAPEUTICS ANNOUNCES POSITIVE INTERIM PHASE 1 RESULTS FROM THE APG990 HEALTHY VOLUNTEER TRIAL, UNLOCKING POTENTIAL MAINTENANCE DOSING EVERY THREE AND SIX MONTHS FOR APG279 (APG777 + APG990)</p></li><li><p>APOGEE THERAPEUTICS INC - APG990 WELL TOLERATED UP TO 1,200MG DOSES</p></li><li><p>APOGEE THERAPEUTICS INC - MOST COMMON ADVERSE EVENT FOR APG990 WAS HEADACHE</p></li><li><p>APOGEE THERAPEUTICS INC - NO SEVERE ADVERSE EVENTS OR STUDY DISCONTINUATIONS FOR APG990</p></li><li><p>APOGEE THERAPEUTICS INC - TO INITIATE PHASE 1B TRIAL OF APG279 AGAINST DUPIXENT IN 2025</p></li></ul><p>Source text: <span>ID:nGNX4V8GW9</span></p><p>Further company coverage: <span>APGE.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"APGE","symbol_name":"Apogee Therapeutics","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250303:nTUAMCKTL:1","article_id":"2516001681","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2516001681","pubTimestamp":1741000231,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BRIEF-Apogee Therapeutics Announces Positive Interim Phase 1 Results From The APG990 Healthy Volunteer TrialMarch 3 (Reuters) - Apogee Therapeutics APGE.O:APOGEE THERAPEUTICS ANNOUNCES POSITIVE INTERI","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"APGE":"Apogee Therapeutics","BK4139":"生物科技"},"translate_title":"简介-Apogee Therapeutics宣布APG990健康志愿者试验的积极中期1期结果","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"APGE":0.9},"content_text":"BRIEF-Apogee Therapeutics Announces Positive Interim Phase 1 Results From The APG990 Healthy Volunteer TrialMarch 3 (Reuters) - Apogee Therapeutics APGE.O:APOGEE THERAPEUTICS ANNOUNCES POSITIVE INTERIM PHASE 1 RESULTS FROM THE APG990 HEALTHY VOLUNTEER TRIAL, UNLOCKING POTENTIAL MAINTENANCE DOSING EVERY THREE AND SIX MONTHS FOR APG279 (APG777 + APG990)APOGEE THERAPEUTICS INC - APG990 WELL TOLERATED UP TO 1,200MG DOSESAPOGEE THERAPEUTICS INC - MOST COMMON ADVERSE EVENT FOR APG990 WAS HEADACHEAPOGEE THERAPEUTICS INC - NO SEVERE ADVERSE EVENTS OR STUDY DISCONTINUATIONS FOR APG990APOGEE THERAPEUTICS INC - TO INITIATE PHASE 1B TRIAL OF APG279 AGAINST DUPIXENT IN 2025Source text: ID:nGNX4V8GW9Further company coverage: APGE.O ((Reuters.Briefs@thomsonreuters.com;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":1}}}